Many of the most-read articles from the print issues of Managed Healthcare Executive® focused on the cost of therapies.
Governments are the only buyers so far, and the amounts they are paying varies.
Screening and some care have been canceled or deferred. Will more illness and deaths result?
Low prices and some gaming of regulations can drive out competitors and create monopolies that allow generic makers to jack up their prices. Experience has shown that it often takes multiple generics to achieve the promised-for downward pressure on prices.
PBMs say exclusions are important for negotiating lower prices on behalf of health plans and members. Some payer and provider groups say they interfere with patient access to medicines.
Having specialty pharmacies fill prescriptions may lower costs, but critics of the practice see safety issues and other drawbacks.
CMS has balked at covering vagus nerve stimulation for treatment-resistant depression. Positive results from an industry-sponsored randomized trial could break the logjam, although it may be several years before results are reported.
Read More
Breaking Down Health Plans, HSAs, AI With Paul Fronstin of EBRI
November 19th 2024Featured in this latest episode of Tuning In to the C-Suite podcast is Paul Fronstin, director of health benefits research at EBRI, who shed light on the evolving landscape of health benefits with editors of Managed Healthcare Executive.
Listen
In this latest episode of Tuning In to the C-Suite podcast, Briana Contreras, an editor with MHE had the pleasure of meeting Loren McCaghy, director of consulting, health and consumer engagement and product insight at Accenture, to discuss the organization's latest report on U.S. consumers switching healthcare providers and insurance payers.
Listen